Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
NOT YET RECRUITING
NCT06438796
PHASE2
Blinatumomab Maintenance After Allo-HSCT
Sponsor: Ruijin Hospital
View on ClinicalTrials.gov
Summary
To evaluate the safety and efficacy of Blinatumomab maintenance after allogeneic hematopoietic stem cell transplantation for high-risk acute B-lymphoblastic leukemia.
Official title: Efficacy and Safety of Blinatumomab Maintenanceafter Allogeneic Hematopoietic Stem Cell Transplantation for High-risk Acute B-lymphoblastic Leukemia: a Multicenter, Open-label, Randomized Controlled Study
Key Details
Gender
All
Age Range
16 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
59
Start Date
2024-07-01
Completion Date
2028-07-01
Last Updated
2024-06-03
Healthy Volunteers
No
Conditions
Interventions
DRUG
Blinatumomab
Maintenance therapy with Blinatumomab initiation: 90 days to 120 days post-transplantation